Polaryx Therapeutics (PLYX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Polaryx Therapeutics (PLYX) is Moderate Underperform.

The composite score behind that read is -0.27, weighing +1.00 of bullish evidence against -0.42 bearish.

Polaryx Therapeutics last closed at $2.10, +1.45% on the session.

Against the IVW growth benchmark the position is +0.84% over the forecast window.

The read is built from 11 underlying insights — 1 bullish and 10 bearish.

Agreement across those insights is 91%.

17 graded predictions for PLYX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Polaryx Therapeutics in the 9th percentile on return on equity, where 100 is best.

Polaryx Therapeutics is classified under Health Care / Pharmaceuticals, with a market capitalisation of $103.18M.

StockMap tracks Polaryx Therapeutics as the 96th largest of the 142 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 61 Moderate Underperform, 57 Neutral, 19 Strong Underperform and 5 Moderate Outperform.

On that composite Polaryx Therapeutics ranks 78th of 142 in the group, against a group median of -0.24.